Clinical Trial Update: Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update describes a master protocol for TCR-modified T cell therapy targeting an HLA-restricted KRAS antigen, studied in adults with metastat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• TCR-modified T cell therapy targeting HLA-restricted KRAS antigen (master protocol)

Snippet

Sponsor: Anocca AB | Conditions: PDAC | Phase 1, Phase 2 | Status: RECRUITING